

Intrasense attends the « Journées Francophones de Radiologie » 2024

Montpellier, France, September 9th, 2024, at 5:45 pm CEST

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian[®] and Liflow[®] developer, announces its attendance in Journées Francophones de Radiologie (JFR) 2024, where will be presented for the first time the new solution Liflow[®] as well as the innovations of the new version of Myrian[®].

Innovations showcased at the JFR 2024

Intrasense will be at the Journées Francophones de Radiologie, the leading trade show for radiology professionals, which will take place from October 4th to October 7th at the Palais des Congrès in Paris. With over 10 000 expected visitors, this 2024 edition will be placed under the « All together for tomorrow's radiology! » theme and will be a great opportunity for Intrasense to present its last technological advances in terms of the medical imaging field's challenges.

The visitors will be able to explore with the new innovative functions of the new solution Liflow[®], first intelligent platform dedicated to the diagnosis and longitudinal monitoring of cancer patients. Marked CE in April, Liflow[®] revolutionizes the oncology monitoring by giving radiologists access to innovative clinical tools enhanced by multi-organ artificial intelligence algorithms, to improve efficiency and diagnosis accuracy.

The new Myrian[®] solution, enriched with AI algorithms dedicated to the prostate and lungs, will also be widely publicized, in a particularly favourable environment in France, where an organized lung cancer screening is launching.

New synergies with GUERBET

This year, Intrasense will have a new strategic location at the show (stand 102A), neighbor to its partner Guerbet, and will fully benefit of the visibility and commercial synergies established between the two companies. This proximity will enlighten the commons developments of cutting-edge solutions for medical imaging and the improvement of health care.

« The first benefits of the synergies established with Guerbet will be on the market this year with the launch of Myrian[®] 2.13 and the regulatory marking of Liflow[®], two solutions including new Ais dedicated to the prostate and liver developed by Guerbet's digital team to meet clinical staff's growing needs. This collaboration allows us to present together innovations that will change medical imaging practice and facilitate a more precise diagnosis and an optimal therapeutic monitoring » says **Alexandre Salvador**, Intrasense CEO.

Greater visibility for innovation

Intrasense will host several symposia on the Guerbet stand. These sessions, designed to attract a broad audience will help with interacting on topics highlighting Intrasense's new solutions:

- **Friday 4 October at 3pm: 'Prostate cancer: how can AI help?'**
This symposium will demonstrate how AI integrated into Myrian® can make prostate diagnosis easier and safer.
- **Saturday 5 October at 3pm: 'Liflow®: the power of multi-organ AI in oncology imaging.'**
Pr. Christophe Aubé, University Professor and Head of the Radiology Department at Angers University Hospital, will discuss the possibilities offered by Liflow® to facilitate oncology analysis.

Intrasense has submitted its application for the JFR 2024 Innovation Prize with Liflow®, in the 'Healthcare IT and Artificial Intelligence' category. This prize, created by the SFR, the SNITEM, Medicen Paris-Région and the French Healthcare Association, aims to promote innovative industrial partners in medical imaging. This award will raise Intrasense's profile as a leader in innovative solutions incorporating AI in medical imaging, demonstrating the excellence and innovation of its solutions for clinicians and patients.

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets software platforms in 40 countries, facilitating and securing diagnosis, decision-making and therapeutic follow-up.

Myrian®, an advanced radiology visualization solution, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing a new platform dedicated to oncology, multidisciplinary and collaborative, to optimize patient care and follow-up.

A Guerbet Group subsidiary since June 2023, Intrasense continues to enrich its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense
Salomé Sylvestre
Communications officer
Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap
Thomas Grojean
Financial Communication
and investor relations
Phone: +331 44 71 20 40

intrasense@newcap.eu